Moleculin Biotech shares are trading higher on Wednesday after the company announced the online publication of preclinical data for its Annamycin Venetoclax Resistant AML model. Dylan Berman ...
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In ...
TipRanks on MSN11d
Alterity Therapeutics Quotes Over 164 Million Securities on ASXMore about Alterity Therapeutics Ltd. Alterity Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of therapies for neurodegenerative diseases. Y ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback